Sign in

CLCS on OTC

Cell Source, Inc.

Cell Source, Inc. is an American pharmaceutical preparations company based in New York.1 Its shares trade on OTC under the symbol CLCS.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerCLCS on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York, New York1
  • Incorporated inNV2
  • Business address57 West 57Th Street, Suite 400, New York, Ny 100192
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Source, Inc. (the “Company”) is a Nevada corporation formed on June 6, 2012 under the name Ticket to See, Inc. (“TTSI”).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$3.8M in 2024+91% since 2018
-$6.0M-$4.0M-$2.0M02018: -$2.0M-$2.0M20182019: -$3.8M-$3.8M2019+90%2020: -$3.6M-$3.6M2020−4%2021: -$4.0M-$4.0M2021+10%2022: -$4.2M-$4.2M2022+4%2023: -$4.3M-$4.3M2023+4%2024: -$3.8M-$3.8M2024−11%
Net income456789-$4.5M in 2024+113% since 2018
-$6.0M-$4.0M-$2.0M02018: -$2.1M-$2.1M20182019: -$4.5M-$4.5M2019+111%2020: -$4.6M-$4.6M2020+2%2021: -$5.5M-$5.5M2021+20%2022: -$5.2M-$5.2M2022−6%2023: -$5.3M-$5.3M2023+3%2024: -$4.5M-$4.5M2024−15%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2024-12-312023-12-31
Loss on legal settlement$142.6K
General and administrative$1.9M$2.6M
Total Operating Expenses$3.8M$4.3M
Loss From Operations-$3.8M-$4.3M
Gain on extinguishment of note payable$17.9K$41.9K
Total Other Expense-$672.4K-$995.9K
Net Loss-$4.5M-$5.3M
Dividend attributable to Series A, B, and C preferred stockholders-$1.4M-$1.2M
Net Loss Applicable to Common Stockholders-$5.9M-$6.5M
Net Loss Per Common Share - Basic-$0.14-$0.17
Net Loss Per Common Share - Diluted-$0.14-$0.17
Weighted Average Common Shares Outstanding - Basic41.9M shares37.8M shares
Weighted Average Common Shares Outstanding - Diluted41.9M shares37.8M shares

Compare Cell Source, Inc. with another company

What it owns

What Cell Source, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

Our corporate headquarters is located at 57 West 57th Street, New York, NY 10019 under an annual lease. The telephone number at such address is (646) 416-7896. We believe that our facilities are adequate and suitable for our current operations. To the extent that other office space is required, we believe that such space is readily available.

Item 2 of the 10-K filed Apr 7, 2026.3

Leadership

Who has led Cell Source, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Itamar Shimrat2015–2016

President

  1. Itamar Shimrat2021

Chief financial officer

  1. Itamar Shimrat2015–2021
20202025
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorDennis Brown named Oct 6, 202319

Former names

  • TICKET TO SEE, INC.Mar 5, 2013 to Jun 26, 20142

Timeline

  1. Jun 27, 20258-K Change of auditor20
  2. Apr 9, 20248-K Other events21
  3. Jul 21, 20228-K Executive or director change22
  4. May 6, 20228-K Executive or director change23
  5. Mar 11, 20228-K Entered a material agreement; Executive or director change24
  6. Apr 1, 2015New chief executive Itamar Shimrat becomes CEO12

Filings

31 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 5 major events, 1 insider forms, 1 private raises, 9 other. The latest 20:

  1. May 14, 202610-Q EDGAR
  2. Apr 7, 202610-K EDGAR
  3. Jul 16, 202515-12G EDGAR
  4. Jun 27, 20258-K EDGAR
  5. Mar 28, 2025NT 10-K EDGAR
  6. Nov 14, 202410-Q EDGAR
  7. Aug 19, 202410-Q EDGAR
  8. Aug 14, 2024NT 10-Q EDGAR
  9. Jul 29, 202410-Q EDGAR
  10. Jun 24, 202410-K EDGAR
  11. Apr 9, 20248-K EDGAR
  12. Apr 1, 2024NT 10-K EDGAR
  13. Nov 9, 202310-Q EDGAR
  14. Oct 6, 2023D EDGAR
  15. Sep 19, 202310-Q EDGAR
  16. Aug 23, 202310-Q EDGAR
  17. Aug 15, 2023NT 10-Q EDGAR
  18. Aug 8, 202310-K EDGAR
  19. May 16, 2023NT 10-Q EDGAR
  20. Mar 31, 2023NT 10-K EDGAR

The 31 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 10, 2020Raised $3.9 million in a private offering of debt Form D: 48 investors so far Form D

SEC filer profile

How Cell Source, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCell Source, Inc.1
  • CIK0001569340
  • Employer ID (EIN)32-03796653
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address57 West 57Th Street, Suite 400, New York, NY 100191
  • Phone646-612-75541
  • Shares outstanding67,945,856 as of May 13, 202611
  • Public float$25.6K as of Jun 30, 20243
  • AuditorCBIZ CPAs P.C., New York, NY PCAOB ID 199; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 5, 20131
  • Filings139 in all: 10-Q (35), 8-K (20), 4 (12), 10-K (11), 3 (8), S-1/A (8), CORRESP (7), NT 10-K (7)1
    All 20 form types

    NT 10-Q (7), UPLOAD (6), D (5), EFFECT (2), S-1 (2), SC 13D (2), SC 13G (2), 10-K/A (1), 15-12G (1), 424B2 (1), 424B3 (1), 8-A12G (1)

  • Latest filingsAnnual report (10-K) Apr 7, 2026
    Quarterly report (10-Q) May 14, 2026
    Latest 8-K (8-K) Jun 27, 2025

Risk factors and legal proceedings

The risks Cell Source, Inc. names in Item 1A of its 10-K filed Apr 7, 2026: 48 risks under these headings, as written.3

  • Risks related to our Business and our Industry
  • We may not receive regulatory approvals for our product candidates or there may be a delay in obtaining such approvals.
  • Clinical trials for our product candidates are expensive and time consuming, and their outcome is uncertain.
  • We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates.
  • Delays in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delay our ability to obtain regulatory approval and commercialize our product candidates.
  • Our product candidates must undergo rigorous clinical testing, the results of which are uncertain and could substantially delay or prevent us from bringing them to market.
  • Preclinical studies and Phase 1 or 2 clinical trials of our product candidates may not predict the results of subsequent human clinical trials.
  • Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization.
  • We are subject to various government regulations.
  • We may become subject to increased government regulation.
  • We may fail to comply with regulatory requirements.
  • Regulatory approval of our product candidates may be withdrawn at any time.
The other 37 risks
  • Even if approved, our products may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition, and results of operations.
  • We do not own any patents and rely on the patents we license from Yeda Research and Development Limited.
  • We are dependent on protecting our proprietary rights.
  • Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.
  • We are dependent on our collaborative partners and service providers the loss of which would hurt our business.
  • If we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably.
  • Our ability and our collaborators’ ability to sell therapeutic products will depend to a large extent upon reimbursement from health care insurance companies.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • Interim, topline, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.
  • We rely on key personnel and, if we are unable to retain or motivate key personnel or hire qualified personnel, we may not be able to grow effectively.
  • We may be subject to foreign exchange fluctuation.
  • We may be exposed to potential product and clinical trials liability.
  • We may become subject to liabilities related to risks inherent in working with hazardous materials.
  • We may in the future conduct clinical trials for our products or product candidates outside the United States and the FDA may not accept data from such trials.
  • Risks Related to Our Capital Resources and Impairments
  • We have a limited operating history and a history of operating losses and expect to incur significant additional operating losses.
  • We will need to secure additional financing.
  • The Russia-Ukraine, Israel-Hamas and United States/Israel-Iran wars have disrupted global markets and my adversely impact our ability to obtain financing.
  • There is substantial doubt about our ability to continue as a going concern.
  • We are an early-stage company with an unproven business strategy and may never achieve commercialization of our candidate products or profitability.
  • We are in default of payment obligations under certain promissory notes.
  • Risks Related to Our Common Stock
  • There may be additional issuances of shares of preferred stock in the future.
  • Our articles of incorporation allow for our board to create a new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our Common Stock.
  • There is not an active liquid trading market for the Company’s Common Stock.
  • Our Common Stock is subject to the “penny stock” rules of the Securities and Exchange Commission, which may make it more difficult for stockholders to sell our Common Stock.
  • We may not be able to attract the attention of brokerage firms because we became a public company by means of a reverse acquisition.
  • Voting power of our shareholders is highly concentrated by insiders.
  • We do not intend to pay dividends to holders of Common Stock for the foreseeable future.
  • Other General Factors
  • Applicable regulatory requirements, including those contained in and issued under the Sarbanes-Oxley Act of 2002, may make it difficult for the Company to retain or attract qualified officers and directors, which could adversely affect the management of its business and its ability to obtain or retain listing of its Common Stock.
  • If we fail to maintain effective internal controls over financial reporting, the price of our common stock may be adversely affected.
  • We are required to comply with certain provisions of Section 404 of the Sarbanes-Oxley Act of 2002 and if we fail to comply in a timely manner, our business could be harmed and our stock price could decline.
  • As an issuer of “penny stock,” the protection provided by the federal securities laws relating to forward looking statements does not apply to us.
  • Our issuance of Common Stock upon exercise of warrants or options may depress the price of our Common Stock.
  • Our stock price may be volatile or may decline regardless of our operating performance, resulting in substantial losses for investors.
  • Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.
  • If we take advantage of specified reduced disclosure requirements applicable to a “smaller reporting company”, the information that we provide to stockholders may be different than they might receive from other public companies.
  • We could be subject to securities class action litigation.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Legal proceedings

We are currently not involved in any pending legal proceeding or litigations and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on us.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
    SEC EDGAROther events
  22. 22
  23. 23
  24. 24